An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

Vista sencilla de ítem
dc.creatorFeng, Liqiang
dc.creatorWang, Qian
dc.creatorShan, Chao
dc.creatorYang, Chenchen
dc.creatorFeng, Ying
dc.creatorWu, Jia
dc.creatorLiu, Xiaolin
dc.creatorZhou, Yiwu
dc.creatorJiang, Rendi
dc.creatorHu, Peiyu
dc.creatorLiu, Xinglong
dc.creatorZhang, Fan
dc.creatorLi, Pingchao
dc.creatorNiu, Xuefeng
dc.creatorLiu, Yichu
dc.creatorZheng, Xuehua
dc.creatorLuo, Jia
dc.creatorSun, Jing
dc.creatorGu, Yingying
dc.creatorLiu, Bo
dc.creatorXu, Yongcun
dc.creatorLi, Chufang
dc.creatorPan, Weiqi
dc.creatorZhao, Jincun
dc.creatorKe, Changwen
dc.creatorChen, Xinwen
dc.creatorXu, Tao
dc.creatorZhong, Nanshan
dc.creatorGuan, Suhua
dc.creatorYuan, Zhiming
dc.creatorChen, Ling
dc.date.accessioned2020-09-18T02:48:24Z
dc.date.available2020-09-18T02:48:24Z
dc.date.created2020-08-21
dc.description.abstractenglishThe rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.spa
dc.format.extent11 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41467-020-18077-5spa
dc.identifier.issn2041-1723spa
dc.identifier.otherhttps://www.nature.com/articles/s41467-020-18077-5spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/13432
dc.language.isoengspa
dc.publisherNature Communicationsspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.keywordVaccinesspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleAn adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaquesspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41467-020-18077-5.pdf
Tamaño:
2.46 MB
Formato:
Adobe Portable Document Format
Descripción:
Ver documento
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS